Results 21 to 30 of about 7,681 (165)

Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France. [PDF]

J Med Virol
ABSTRACT Lenacapavir and fostemsavir, two recently approved anti‐HIV‐1 agents, are promising options for people with difficult‐to‐treat HIV; however, real‐world data remain limited. This study aimed to describe the epidemiological, clinical, and virological profiles of people receiving combination antiretroviral regimens, including lenacapavir and/or ...
Boujamline S, Boschi C, Bes-Barlandier H, Tomei C, Menard A, Mokhtari S, Ravaux I, Belkhir Y, Neant N, Solas C, Colson P, Million M.   +11 more
europepmc   +2 more sources

Chemokine Receptor 5 Antagonism Causes Reduction in Joint Inflammation in a Collagen-Induced Arthritis Mouse Model

Molecules, 2021
Rheumatoid arthritis (RA) is a chronic inflammatory disease mainly affecting the synovial joints. A highly potent antagonist of C-C chemokine receptor 5 (CCR5), maraviroc (MVC), plays an essential role in treating several infectious diseases but has not ...
Mushtaq A. Ansari, Ahmed Nadeem, Saleh A. Bakheet, Sabry M. Attia, Mudassar Shahid, Faris S. Alyousef, Mohammed A. Alswailem, Mohammed Alqinyah, Sheikh F. Ahmad   +8 more
doaj   +1 more source

Virological failure of patients on maraviroc-based antiretroviral therapy [PDF]

, 2015
International audienceOBJECTIVES: Virological failure (VF) in patients on maraviroc-based treatment has been associated with altered HIV tropism and resistance to maraviroc.
Marcelin, Anne Geneviève, Amiel, Corinne, Peytavin, Gilles, Descamps, Diane, Izopet, Jacques, Trabaud, Mary Anne, Delaugerre, Constance, Raymond, Stéphanie, Soulie, Cathia, Maillard, Anne, Desbois, Delphine, Bellecave, Pantxika   +11 more
core   +1 more source

Interactions between Alcohol and the HIV Entry Inhibitor Maraviroc [PDF]

, 2013
BACKGROUND: Alcohol use is common among people with HIV, and beliefs about alcohol interactions with medications predict decreased medication adherence, risking drug-resistant mutations.
Rainey, Petrie M, Aweeka, Francesca T, Lum, Paula J, Beatty, George W, Gruber, Valerie A, McCance-Katz, Elinore F   +5 more
core   +1 more source

Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women [PDF]

, 2015
Objective.To describe the pharmacokinetics of maraviroc in human immunodeficiency virus (HIV)-infected women during pregnancy and post partum. Methods.HIV-infected pregnant women receiving maraviroc as part of clinical care had intensive steady-state 12 ...
Van Der Ende, Marchina, Hakim, Alejandro, Knapp, Katherine K.M., Gilleece, Yvonne, Wiznia, Andrew, Alvarez, Janielle Jackson, Colbers, Angela P H, Nellen, Jeannine F J B J., Nicastri, Emanuele, Wride, Thomas, Lewis, Gail, Rockstroh, Jürgen, Tamayo, Vivian, Febo, Irma I.L., Giaquinto, Carlo, Losso, Marcelo, van der Ven, André J A M A.J.A.M., Sadiq, Syed Tariq, Florez, Claudia, Moltó, José, Katz, Mindy, Lambert, John, Deveikis, Audra, Wood, Chris G A C., Jackson, Chivon, Wyen, Christoph, Bruder, Karen K.L., Bryan, Patricia, Erasmus, M., Gingelmaier, Andrea, Auguste, Raphaelle, Faetkenheuer, Gerd, Batra, Jagmohan, Schwarze-Zander, Carolynne, Kabeya, Kabamba, Lyons, F., Buschur, Shelley, Sublette, Nina, Ivalo, Silvina S.A., Stone, Monica, Casey, Denise, Santos, Ruth, Paul, Mary   +42 more
core   +2 more sources

A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects.

PLoS ONE, 2019
Effects of steady-state rifabutin on the pharmacokinetics of steady-state maraviroc were investigated in fourteen healthy adult female and male volunteers. Maraviroc 300 mg twice daily (BID) was given orally with food for fifteen days.
M Ghannad, M Dennehy, C la Porte, I Seguin, D Tardiff, R Mallick, E Sabri, G Zhang, S Kanji, D W Cameron   +9 more
doaj   +1 more source

Tropism prediction in HIV-1 variants circulating in Cuba, 2017-2019: Implications for the pathogenesis of infection and response to Maraviroc

Journal of Microbiology and Infectious Diseases, 2023
Background: Tropism is determined by the ability of HIV-1 to bind to the receptors CCR5 or CXCR4 to enter the target cell, which has implications for the pathogenesis of the disease and affects treatment options.
Anamary Suarez Batista, Lissette Perez Santos, Liuber Yans Machado Zaldívar, Melissa Mendez Gonzalez, Yanet Pintos Saavedra, Jorge Perez Ávila, Hector Manuel Díaz Torres, Tamara Rojas Nuñez, Juliet María Enriquez Puertas, Yoanna Baños Morales, Enrique Noa Romero, Vivian Kourí Cardella   +11 more
doaj   +1 more source

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.

PLoS ONE, 2018
Detailed clonal phenotypic/genotypic analyses explored viral-escape mechanisms during maraviroc-based therapy in highly treatment-experienced participants from the MOTIVATE trials. To allow real-time assessment of samples while maintaining a blind trial,
Marilyn Lewis, Julie Mori, Jonathan Toma, Mike Mosley, Wei Huang, Paul Simpson, Roy Mansfield, Charles Craig, Elna van der Ryst, David L Robertson, Jeannette M Whitcomb, Mike Westby   +11 more
doaj   +1 more source

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification

Journal of Virus Eradication, 2015
Background: It is unclear whether intensification of standard highly active antiretroviral therapy (HAART) with entry and integrase inhibitors during acute HIV infection (AHI) could yield greater benefits in reducing markers for HIV reservoir size and ...
Jintanat Ananworanich, Nicolas Chomont, James L.K. Fletcher, Suteeraporn Pinyakorn, Alexandra Schuetz, Irini Sereti, Rungsun Rerknimitr, Robin Dewar, Eugene Kroon, Claire Vandergeeten, Rapee Trichavaroj, Nitiya Chomchey, Thep Chalermchai, Nelson L. Michael, Jerome H. Kim, Praphan Phanuphak, Nittaya Phanuphak   +16 more
doaj   +1 more source

CCR5 is a novel target for the treatment of experimental alopecia areata

Journal of Cutaneous Immunology and Allergy, 2020
Background Alopecia areata (AA) is an organ‐specific and cell‐mediated autoimmune disease. Hair follicle autoantigens are disclosed to these autoreactive NKG2D+CD8+ T cells.
Taisuke Ito, Takahiro Suzuki, Atsuko Funakoshi, Toshiharu Fujiyama, Yoshiki Tokura   +4 more
doaj   +1 more source